Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
1. TVGN's asset TVGN 116 rNPV exceeds $325 million for liver cancer prevention. 2. Projected 5-year revenue for TVGN 116 is approximately $6.5 billion. 3. Tevogen's fast drug development model may influence future innovation. 4. Progress with TVGN 489 highlights Tevogen's capability in product development. 5. Forward-looking statements carry inherent risks and uncertainties affecting outcomes.